Telaprevir clinical trials
Also written VX-950, Incivek, MP-424 and INCIVO.
How each study uses telaprevir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 23 May 2011 · INCIVEK · NDA 201917 (FDA, Drugs@FDA)
- European Union
- 19 Sept 2011 · Incivo · EMEA/H/C/002313 (EMA; now expired)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
64 studies that test it; most in 2012 (18)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 9 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 8 |
| 2012 | 18 |
| 2013 | 10 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 51 · Other 13
Vertex Pharmaceuticals Incorporated (17) · Tanabe Pharma Corporation (10) · Tibotec BVBA (6) · Janssen-Cilag International NV (4) · Janssen Infectious Diseases BVBA (4) · Bristol-Myers Squibb (2) · Santaris Pharma A/S (2) · ANRS, Emerging Infectious Diseases (1)
Often tested with
Tested in the same studies.
Ribavirin (20) · Peginterferon alfa-2a (10) · Peginterferon alfa-2b (4) · Boceprevir (3) · Daclatasvir (2) · Miravirsen (2) · Lomibuvir (2) · Interferons (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses telaprevir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 64
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT01332955Written as Telaprevir
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00781274Written as MP-424
- Safety and PK Study of MP-424 to Treat Chronic Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00591214Written as MP-424 (Telaprevir)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01466192Written as MP-424 (generic name:Telaprevir)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT01753557Written as MP-424
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00630058Written as MP-424(H), PEG-IFN-a-2b, RBV
- Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CCompletedPhase 2Tanabe Pharma CorporationNCT00621296Written as MP-424 (Telaprevir)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT00780416Written as MP-424
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00780910Written as MP-424
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01468584Written as MP-424 (generic name:Telaprevir)
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedPhase 3Tanabe Pharma CorporationNCT01753570Written as MP-424
- Telaprevir in Genotype 3 HCVCompletedPhase 4Queen Mary University of LondonNCT02087111Written as Telaprevir
- A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT00758043Written as telaprevir
- Interaction Between Paroxetine and TelaprevirTerminatedPhase 2Radboud University Medical CenterNCT01841502Written as telaprevir
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedPhase 2Vertex Pharmaceuticals IncorporatedNCT01080222Written as telaprevir
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)TerminatedPhase 3M.D. Anderson Cancer CenterNCT01821963Written as Telaprevir
- Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1CompletedPhase 2University of FloridaNCT01994486Written as Telaprevir and Sofosbuvir
- Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01657552Written as Telaprevir
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC PolymorphismWithdrawnPhase 4University of VermontNCT01415141Written as telaprevir
- Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)CompletedPhase 3St Stephens Aids TrustNCT02006745Written as Telaprevir
See all 64 studies that test telaprevir →
Given beside what is tested · 11 — telaprevir is usual care or a partner of the new treatment
- Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis CTerminatedPhase 2MassBiologicsNCT01532908Written as Telaprevir (Part 1)
- Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedPhase 3Bristol-Myers SquibbNCT01598090Written as Telaprevir
- Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501CompletedPhase 2Eisai Inc.NCT01355289Written as Telaprevir
- A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01482390Written as Telaprevir
- A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).CompletedPhase 1ViiV HealthcareNCT01563328Written as TVR
- A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01516918Written as telaprevir
- VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01581138Written as telaprevir
- An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C ParticipantsCompletedPhase 2Tibotec BVBANCT00528528Written as Telaprevir
- Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1WithdrawnPhase 2/3Timothy Morgan, MDNCT01890772Written as Telaprevir
- A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard TreatmentCompletedPhase 3Tibotec BVBANCT00703118Written as Telaprevir
- A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01038167Written as telaprevir
As the comparator · 4 — what is tested is compared with telaprevir
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as Telaprevir
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced AdultsCompletedPhase 3AbbVieNCT01854528Written as Telaprevir
- Dose Ranging of GSK2336805 in Combination TherapyCompletedPhase 2GlaxoSmithKlineNCT01648140Written as Telaprevir
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01718145Written as Telaprevir
Codes
What other systems call telaprevir · ClinicalTrials.gg INT004648
- MeSH (NLM) C486464telaprevirConfirmed NLM, Wikidata
- UNII (FDA) 655M5O3W0UTELAPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1102261Confirmed FDA, Wikidata
- Wikidata Q408557telaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81603TelaprevirOne source FDA
- DrugBank DB05521One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C486464 | telaprevir | Confirmed NLM, Wikidata |
| UNII (FDA) | 655M5O3W0U | TELAPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1102261 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408557 | telaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81603 | Telaprevir | One source FDA |
| DrugBank | DB05521 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.